top of page

The 15-Year Warning: Why We Need to Measure Lung Decline in Traffic Jams, Not Clinic Waiting Rooms

Insights from Bipin Patel, CEO & Founder

October 2nd, 2025

Here's something that keeps me awake at night: Right now, someone is sitting in traffic, perhaps on the M25, perhaps on their daily commute to work, and their lungs are 15 years older than they think. They won't know it for another decade. By the time they're breathless climbing stairs at 65, they'll have already lost 40% of their lung function. And the truly maddening bit? We could have told them at 50. I've spent the last ten years developing technology to address this issue, and what I've learned has fundamentally altered my perspective on respiratory health. It's not that we lack the science to understand lung ageing, we've had robust equations and validation studies for decades. The problem is far simpler and far more stubborn: we're measuring the right thing in the wrong place at the wrong time. Let me explain.


The Invisible Epidemic Nobody's Talking About

We all accept that our bodies age. Grey hair, reading glasses, the occasional creak in the knees, these are visible, tangible reminders. But your lungs? They're ageing too, and unlike your hairline, you can't see it happening until it's already done considerable damage.


The research here is unambiguous. Studies using data from the Third National Health and Nutrition Examination Survey show that the lung age deficit, the gap between your chronological age and your lungs' biological age, begins to accelerate in your twenties if you smoke, with a rapid acceleration thereafter [1]. But here's what caught my attention: even in never-smokers with normal spirometry, there's remarkable variability. Some people are born with Olympic-level lungs, while others start behind the curve. And none of us know which category we're in unless we test.


The cellular story underneath makes this urgency even more compelling. As lungs age, they undergo profound changes, including decreased elastic recoil, increased airspace dilation and altered immune responses [2]. The fascinating, and slightly unsettling, bit is that many of these changes mirror what we see in chronic obstructive pulmonary disease (COPD). Ageing itself accelerates lung disease. Disease accelerates ageing. It's a continuum, not a binary.


Yet, for most people, their first spirometry test happens when they're already symptomatic. By then, we're managing decline, not preventing it.


The Gap: Why Annual Check-Ups Aren't Enough

Let me put this in terms that resonate with my engineering background. Imagine checking your bank account once a year or even once every three years. You might notice if you've gone bankrupt, but you'd miss every trend, every warning sign, every opportunity to course-correct. That's what we're doing with lung function.


Traditional spirometry is brilliant; it's the gold standard for a reason. However, it requires specialised equipment, a trained technician to guide you through forced maximal exhalations, and a clinical setting. For home monitoring, the adherence challenge is a genuine concern. Ask any respiratory physician about home spirometry compliance, and they'll tell you: without encouragement, patients struggle to perform the manoeuvres correctly, which means that the data is often unreliable.


But here's where the science gets interesting. Recent research on spirometric-derived lung age (SDL age) has revealed a remarkable finding: once a measurement system is calibrated to an individual, it achieves significant internal consistency [3]. You're not trying to compare Patient A to population norms, you're comparing Patient A today to Patient A last week. That's a fundamentally different paradigm.


The Japanese Respiratory Society, building on decades of work refining lung age equations, has demonstrated that tracking lung age over time can detect trends far earlier than waiting for absolute FEV₁ values to drop below clinical thresholds [3]. One study noted that with frequent measurements, decline patterns can be identified in months rather than the 2.5 years typically required with annual spirometry [3].


Think about what that means. For someone with early COPD, interstitial lung disease, or accelerated ageing due to occupational exposure, we can see the curve changing in near real-time. This would enable us to intervene when it actually matters.


The Automotive Revolution You Haven't Heard About

Now, let me bring this back to where I started: that person sitting in traffic.

The automotive sector has undergone a remarkable transformation over the last decade. Modern vehicles monitor driver drowsiness through steering patterns, track stress through heart rate variability measurements, and even adjust cabin environments based on biometric feedback. The connected car isn't science fiction, it's in your garage.


But here's what nobody's talking about: the most significant health threat in your car isn't your driving. It's what you're breathing in.

Traffic pollution, cabin air quality, and cumulative exposure over years of commuting can have measurable impacts on lung function. And while your car knows when it needs an oil change, it has no idea that your lungs are ageing faster than they should be.


Imagine a different scenario. You're driving to work, and your vehicle prompts you for a 60 second breathing assessment. You breathe normally, no forced exhalations, no complex manoeuvres, while a camera captures chest wall movement and respiratory patterns. The system analyses your lung age, compares it to your baseline from last week, and correlates it with route selection and cabin air filtration performance.


If your lung age is trending upward, the system gently suggests: "Your respiratory health markers have changed. Consider scheduling a check-up." Not alarmist. Not medical advice. Just data-driven awareness.

For automotive companies exploring in car health and wellness as a service, this is no mere futurism. The technology exists. The validation studies exist. What's needed is the will to implement it.

Pulmonary Hypertension Infographic.png

The Insurance Case: Early Data, Early Intervention, Better Outcomes

Let's talk economics. Lung disease costs the global economy over $2 trillion annually. For insurers, respiratory conditions represent a significant portion of long-term claims, hospitalisations, and mortality risk.

But here's the opportunity: lung age isn't a static genetic risk factor. It's dynamic. It responds to behaviour change.


Quit smoking, and your lung age trajectory changes. Start exercising, and you see measurable improvements. Reduce exposure to occupational pollutants, and the decline slows. Unlike genomic risk scores, which tell you what might happen but offer limited intervention pathways, lung age tells you what is happening and gives you advice on how to change it.


For insurers, this creates a fundamentally different value proposition. Instead of simply pricing risk retrospectively, imagine rewarding proactive health monitoring. Policyholders who regularly track their lung age and demonstrate stable or improving trends may qualify for premium adjustments. Those showing concerning trajectories could be offered early intervention programs, including pulmonary rehabilitation, smoking cessation support, and air quality consultations.


The research supports this approach. Studies have shown that lung age deficit predicts mortality and morbidity with remarkable accuracy. It's a leading indicator, not a lagging one. And crucially, it's modifiable.

This isn't about penalising people for ageing, we all age. It's about creating incentives for awareness and interventions while there's still time to make a difference.


The Government Imperative: Population Health at Scale

From a public health perspective, the lung age opportunity becomes even more compelling. Governments facing ageing populations and rising healthcare costs need scalable solutions for identifying at-risk individuals before they become acute cases.


Consider occupational health. Workers in construction, mining, manufacturing, and emergency services are exposed to cumulative respiratory hazards that accelerate lung ageing. But monitoring typically happens reactively, after someone develops symptoms. What if we could track lung age trends across entire workforces, identifying hotspots and intervention opportunities years earlier?


Or consider air quality. We are aware that specific communities face disproportionate exposure to pollution. However, mapping environmental exposure differs from measuring biological impact. Lung age monitoring in affected populations could provide the evidence base for policy interventions, from traffic management to industrial regulation.


The technology enables something that has never been possible before: longitudinal respiratory health surveillance at a population scale, with the granularity to identify individual risk and the aggregation to inform policy.

And here's the bit that really matters: accessibility. Traditional spirometry requires infrastructure, including clinics, equipment, and trained staff. For underserved communities, rural populations, or regions with limited healthcare access, that's a significant barrier. But video-based lung age assessment? It requires a smartphone. That's not just convenient, it's equitable.


Where Do We Go From Here?

I want to be very clear about our current position. At electronRx, we do not claim to replace clinical spirometry. We're not suggesting that lung age should be the only metric physicians consider. What we're building is something complementary: a tool for frequent, accessible monitoring that sits between "nothing" and "annual clinic visits."


The science is solid. The validation studies are encouraging. We're working toward Class 2A medical device certification, and we're collaborating with respiratory physicians to ensure clinical utility, not just technical agreement.

But the bigger conversation, the one I want to start with this piece, is about the paradigm itself. Why do we accept that lung health monitoring should be annual, clinic-based, and reactive? Why shouldn't it be daily, accessible, and proactive?


The average person will take about 670 million breaths in their lifetime. Shouldn't we know if those breaths are becoming more difficult before it's too late to do anything about it?


That person sitting in traffic, the one with lungs ageing faster than they realise, doesn't need another lecture about air quality. They need data. They need awareness. They need the option to act while there's still time.

We built the technology to give them that option. Now we need the automotive industry, insurers, health systems, and governments to help us make it accessible.


Because here's the truth: we have the science to detect lung decline 15 years before symptoms appear. We have the technology to measure it in 60 seconds with a smartphone. And we have validated equations that can track changes with remarkable precision.


What we need now is the collective will to use it.

The question isn't whether we can monitor lung age during your daily commute. The question is: why aren't we already?

blue heart (3).png

Get In Touch

Interested in strategic collaborations? Let’s discuss how electronRx can support your respiratory pipeline

References

[1] Hansen J. Lung age is a useful concept and calculation. Prim Care Respir J. 2010 Dec;19(4):400-1; author reply 401. doi: 10.4104/pcrj.2010.00074. PMID: 21042695; PMCID: PMC6602464.

[2] Cho SJ, Stout-Delgado HW. Aging and Lung Disease. Annu Rev Physiol. 2020 Feb 10;82:433-459. doi: 10.1146/annurev-physiol-021119-034610. Epub 2019 Nov 15. PMID: 31730381; PMCID: PMC7998901.

[3] Ishida Y, Ichikawa YE, Fukakusa M, Kawatsu A, Masuda K. Novel equations better predict lung age: a retrospective analysis using two cohorts of participants with medical check-up examinations in Japan. NPJ Prim Care Respir Med. 2015 Mar 19;25:15011. doi: 10.1038/npjpcrm.2015.11. PMID: 25789796; PMCID: PMC4373493.

bottom of page